The in vitro potency of BAL 9141, a new pyrrolidinone cephalosporin, was tested against nonduplicate strains of anaerobic bacteria. The MIC 50 was 1 mg/L against Actinomyces species,
Introduction
BAL 9141 is a new broad-spectrum pyrrolidinone-3-ylidene-methyl cephalosporin active against methicillinresistant Staphylococcus aureus. The MIC 90 for methicillinresistant S. aureus (MRSA) is 4 mg/L and BAL 9141 is bactericidal against MRSA in a time-dependent manner. BAL 9141 is more potent than cefotaxime against strains of Streptococcus pneumoniae with reduced susceptibility to penicillin and has equivalent activity to ceftazidime against Pseudomonas aeruginosa. It is not active against all strains of Escherichia coli or Klebsiella pneumoniae that produce extended-spectrum -lactamases or Proteus vulgaris. 1 Animal studies of MRSA experimental endocarditis have indicated that BAL 9141 is more effective than either coamoxiclav or vancomycin. 2 Little is known about its activity against anaerobic bacteria, which remain important human pathogens, being associated with intra-abdominal, pulmonary, head, neck, soft tissue, intracerebral and bloodstream infection. In many areas of the world, -lactams such as piperacillin/tazobactam, co-amoxiclav, cefoxitin, cefotetan and meropenem or imipenem are used in therapy or prophylaxis of mixed aerobic and anaerobic infection. Hence, it is important to establish the potential activity of new -lactams such as BAL 9141 against this pathogen group.
Materials and methods
Three hundred and forty-four anaerobe isolates were tested. These were clinical isolates from this Centre or from the PHLS Anaerobic Reference Laboratory, Cardiff, UK. The following control strains were used: Bacteroides fragilis ATCC 25285, Clostridium perfringens NCTC 1229, Peptostreptococcus magnus ATCC 14956, S. aureus ATCC 9144 and E. coli ATCC 10536. The antibiotics used were obtained from the following manufacturers: piperacillin/ tazobactam (Wyeth, Maidenhead, UK); co-amoxiclav and ticarcillin/clavulanate (GlaxoSmithKline, Uxbridge, UK); cefoxitin (MSD, Hoddesdon, UK), cefotetan and meropenem (AstraZeneca, Luton, UK); ceftazidime (GlaxoSmithKline); metronidazole (PMU Healthcare, Exeter, UK) and BAL 9141, cefoperazone/sulbactam, ceftriaxone (F. Hoffmann-La Roche, Basel, Switzerland). Susceptibilities were determined by the standard agar incorporation method recommended by the BSAC. 3 Agar dilution MICs were performed on Wilkins-Chalgren agar (CM 619; Unipath, Basingstoke, UK) supplemented with 5% lysed horse blood. The antibiotics were incorporated into the media in a log 2 series from 0.008-128 mg/L. -Lactamase inhibitors were used at a fixed concentration of 4 mg/L. The inocula were prepared by dilution in a saline suspension equivalent to McFarland 0.5 standard, 1 in 10, which resulted in 10 4 cfu/spot when applied by a Denley multipoint inoculator. The plates were incubated at 37ЊC for 40 h in a Wise anaerobic workstation (Don Whitley Scientific, Shipley, UK) in an atmosphere of 80% N 2 , 10% H 2 and 10% CO 2 , and were read by eye in comparison with an antibiotic-free control plate. The MIC was defined as the lowest concentration of drug to inhibit macroscopically visible colonies. MICs of -lactam--lactamase inhibitor combinations were expressed as the concentration of the -lactam in the combination.
Results and discussion
The g P. bivia (10), P. buccae (9), P. oralis (7), P. buccalis (3), P. corporis (1), P. denticola (2) , P. disieris (3), P. intermedia (1), P. loescheii (4), P. oris (3), P. zoogleoformans (1) .
Bacteroides species (MIC 50 8 mg/L). In general, the penicillins (co-amoxiclav, piperacillin/tazobactam and ticarcillin/ clavulanate) had lower MIC 50 s against all the genera than the cephalosporins and meropenem was the most potent -lactam tested. Metronidazole was an active agent in all groups except Actinomyces species and Lactobacillus species.
The susceptibility of the Bacteroides species were analysed further based on cefoxitin MICs (Figure) . The MIC 50 s of BAL 9141, cefotetan, piperacillin/tazobactam, co-amoxiclav and meropenem all increased as the cefoxitin MIC increased.
No study has reported the in vitro activity of BAL 9141 against human anaerobic pathogens. In terms of MIC 50 s, BAL 9141 was similar to that of cefoxitin; activity was superior to cefotetan and cefperazone/sulbactam against most species, and was almost always superior to ceftazidime and ceftriaxone. However, the activity of BAL 9141 was notably poorer than cefoxitin against Bacteroides spp., and MIC 50 s were higher for BAL 9141 against B. fragilis than cefoxitin and cefotetan. In terms of MIC 90 s, BAL 9141 had clearly inferior activity to cefoxitin against most genera and was not more active against members of the B. fragilis group that had reduced cefoxitin susceptibility.
However, antimicrobial clinical efficacy does not depend exclusively on in vitro potency. Owing to insufficient solubility, in man BAL 9141 will be administered as a prodrug that is rapidly cleared in the blood to BAL 9141, which has a human protein binding of 38%. 1 Early pharmacokinetic studies in a range of animals indicate a volume of distribution (V d ) at steady state of 0.25-0.36 L/kg, and have suggested that the half-life in man will be in the range 2-3 h, with urinary excretion likely. 4 Once human pharmacokinetic studies and pharmacodynamic modelling data become available, it will be easier to predict the possible role for BAL 9141 in the management of human anaerobic infection. Such speculation can only be confirmed by well conducted clinical trials. ٗ, piperacillin/tazobactam; ᭺, co-amoxiclav; ϫ, meropenem.
